EpiAxis in the media
Get In Touch
There is a substantial unmet clinical need when it comes to fighting recurrent, metastatic breast cancer. This is the major cause of death in women with breast cancer. We aim to address that unmet need by the novel targeting of breast cancer stem cells, which are resistant to conventional systemic anticancer therapies and therefore contribute to the failure of these therapies in patients.
Professor Sudha Rao
Founder at EpiAxis Therapeutics